Wroclaw-based Biotts to revolutionise drug and vaccine delivery

• Biotts develops innovative carriers of medicinal substances. This technology may be used in the future as a transport system for, among others, commonly used oncology drugs, diabetes drugs and even vaccines.
• The Wroclaw-based company has expanded the potential of the transdermal market. Thanks to the developed carrier, it will be possible to transport molecules deep into the skin, the transfer of which has so far been impossible.

Biotts biotechnology startup

A team of Biotts technologists, a company operating in the Wroclaw Technology Park at ul. Duńska, has developed an original technology for obtaining a universal transdermal therapeutic system. As the representatives of the Wroclaw-based company explain, the unique properties of the system increase bioavailability of active substances several times, enabling their penetration through skin barriers into the body in a controlled manner, including reaching soft tissues and bones.

The transdermal system developed by the company will enable the transport of even several active substances simultaneously, thanks to which it is possible to design, for example, multi-ingredient drugs.

- Among other things, we are currently working on investigating non-invasive possibilities of transporting protein and peptide substances through the skin. This is a new path of development, which in the future may be used to create a new platform for delivery of vaccines, including COVID-19. Research on transfer of two peptide molecules into the bloodstream of small laboratory animals has been successfully completed, the next stage is research on large animals, and finally on humans. At the same time, work is underway to confirm the effective action of natural plant extracts in the prevention and treatment of viral infections - says Paweł Biernat, President of Biotts.

Biotts Polish company with innovative MTC-Y technology

Biotts scientists from Wroclaw explain that the universal MTC-Y carrier (Multifunctional Transdermal Carrier-Y), on the basis of which the team creates original drug formulations, acts directly on the pathologically changed tissues, guaranteeing a stronger therapeutic effect, while reducing side effects and increasing patient comfort.

- Taking medication is cumbersome - you have to remember about it and the injections are painful. Administration of pharmaceuticals in the form of a patch, ointment, gel or cream, which release the active substance over several days, is an ideal solution for parents administering drugs to their children, for patients, for example, with diabetes. Scientists do not exclude that faster and non-invasive administration of vaccines, e.g. for Covid-19, will also be possible with the Biotts system - thanks to this technology, the costs of treatment and vaccinations will be reduced, and the comfort of life of millions of patients will be increased. The goal is a future without pills and injections - say Biotts scientists from Wroclaw.

Biotts - a future without pills and injections

• Biotts currently operates on the international market in two therapeutic areas: diabetes and oncology.
• Biotts provides research and development services for pharmaceutical and biotechnological companies from all over the world.

Polish scientists signed an agreement with the American Tapemark at the turn of February and March 2021. It is a world leader in developing complex transdermal drug delivery patches, and they are also in talks with other international companies. Read also: Wroclaw-based Biotts and US-based Balanced Biotech are fighting breast cancer.

• We have started cooperation with Tapemark on the creation and commercialisation of application technology for the proprietary MTC-Y carrier, which allows the delivery of large molecules through the skin - Konrad Krajewski, managing partner at Biotts.

The team from Wroclaw has already delivered many solutions to the market, including: a non-aggregating nanocarrier used in the production of vitamin preparations, formulations of anti-allergic preparations, semi-solid formulations of drug forms with a carrier with deep penetration and accelerating tissue reconstruction. Read also: Development of anti-diabetic therapies and drugs through the skin. Wroc³aw-based Biotts with a project worth 15 million PLN.

Biotts: biotechnology market worth billions

Representatives of Biotts, a Wroclaw-based company, emphasise that the biotechnology market has been demonstrating high growth dynamics for several years - globally, the segment of transdermal systems alone is estimated to reach USD 6bn in 2027.

This growth is driven by the increasing prevalence of chronic diseases and technological advances in transdermal drug delivery systems (according to the Markets and Markets report). Transdermal patches account for 84% of this segment, semi-permanent drug forms for 16%. 91% of patients of transdermal systems are home users, 9% hospitals and clinics (according to a report by Grand View Research).

Biotts made in Wroclaw. Treatment through the skin

Biotts is a Wroclaw-based biotechnology company developing proprietary drug delivery technologies and drug formulations in the areas of oncology, dermatology and autoimmune diseases. Biotts' team of technologists has developed an original technology for obtaining a universal transdermal therapeutic system.

• The unique properties of the system increase bioavailability of active substances several times, enabling them to penetrate skin barriers up to several centimetres, thus reaching soft tissues and bones.
• Biotts' unique transdermal system enables the transport of one or more active substances, making it possible to design multicomponent drugs.

Biotts also provides research and development services on behalf of pharmaceutical, biotechnology, cosmetic and chemical companies from around the world. Biotts is the author and sole copyright holder of four patent applications, two of which have entered the global PCT protection procedure. Read also: Biotts, a technology bringing a revolution in medicine.